Mark A. Velleca

2020 - G1 Therapeutics

In 2020, Mark A. Velleca earned a total compensation of $4M as Former Chief Executive Officer and President at G1 Therapeutics, which was about the same as previous year.

Compensation breakdown

Non-Equity Incentive Plan$305,000
Option Awards$3,069,704
Salary$608,308
Other$8,550
Total$3,991,562

Velleca received $3.1M in option awards, accounting for 77% of the total pay in 2020.

Velleca also received $305K in non-equity incentive plan, $608.3K in salary and $8.6K in other compensation.

Rankings

In 2020, Mark A. Velleca's compensation ranked 2,858th out of 13,090 executives tracked by ExecPay. In other words, Velleca earned more than 78.2% of executives.

ClassificationRankingPercentile
All
2,858
out of 13,090
78th
Division
Manufacturing
1,101
out of 5,618
80th
Major group
Chemicals And Allied Products
406
out of 2,251
82nd
Industry group
Drugs
350
out of 1,951
82nd
Industry
Pharmaceutical Preparations
256
out of 1,456
82nd
Source: SEC filing on April 28, 2021.

Velleca's colleagues

We found five more compensation records of executives who worked with Mark A. Velleca at G1 Therapeutics in 2020.

2020

Soma Gupta

G1 Therapeutics

Chief Commercial Officer

2020

Jennifer Moses

G1 Therapeutics

Chief Financial Officer

2020

Mark Avagliano

G1 Therapeutics

Chief Business Officer

2020

Rajesh Malik

G1 Therapeutics

Chief Medical Officer

2020

John Bailey

G1 Therapeutics

Chief Executive Officer

News

In-depth

You may also like